Design Therapeutics, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price
Design Therapeutics, Inc. (DSGN) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price of $5.20 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice · last filed 2026-08-03
- Design Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2026-03-31 was $4.10, a 153.09% increase year-over-year.
- Design Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2025-03-31 was $1.62, a 70.53% increase year-over-year.
- Design Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2024-03-31 was $0.95, a 9400.00% increase year-over-year.
- Design Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for the quarter ending 2023-03-31 was $0.01, a 99.36% decline year-over-year.
- Design Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2025 was $3.37, a 254.74% increase from fiscal 2024.
- Design Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2024 was $0.95, a 1.06% increase from fiscal 2023.
- Design Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2023 was $0.94, a 34.27% decline from fiscal 2022.
- Design Therapeutics, Inc. share-based compensation arrangements by share-based payment award, options, exercises in period, weighted average exercise price for fiscal 2022 was $1.43, a 120.00% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.20 10-Q · filed 2026-08-03 | |||
| 2026-03-31 | $4.10 10-Q · filed 2026-04-28 | |||
| 2025-12-31 | $3.37 10-K · filed 2026-03-09 | |||
| 2025-09-30 | $2.01 10-Q · filed 2025-11-05 | |||
| 2025-06-30 | $1.62 10-Q · filed 2025-08-07 | |||
| 2025-03-31 | $1.62 10-Q · filed 2025-05-07 | |||
| 2024-12-31 | $0.95 10-K · filed 2025-03-10 | |||
| 2024-09-30 | $0.95 10-Q · filed 2024-11-07 | |||
| 2024-06-30 | $0.95 10-Q · filed 2024-08-05 | |||
| 2024-03-31 | $0.95 10-Q · filed 2024-05-08 | |||
| 2023-12-31 | $0.94 10-K · filed 2024-03-19 | |||
| 2023-09-30 | $0.81 10-Q · filed 2023-11-13 | |||
| 2023-06-30 | $0.56 10-Q · filed 2023-08-14 | |||
| 2023-03-31 | $0.01 10-Q · filed 2023-05-09 | |||
| 2022-12-31 | $1.43 10-K · filed 2024-03-19 | |||
| 2022-09-30 | $1.50 10-Q · filed 2022-11-03 | |||
| 2022-06-30 | $1.53 10-Q · filed 2022-08-08 | |||
| 2022-03-31 | $1.56 10-Q · filed 2022-05-09 | |||
| 2021-12-31 | $0.65 10-K · filed 2023-03-14 | |||
| 2020-12-31 | $0.95 10-K · filed 2022-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |